Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease: A cross-sectional study

Masoomeh Sabaei; Saba Rahimian; Arsh Haj Mohamad Ebrahim Ketabforoush; Homa Rasoolijazi; Babak Zamani; Fahime Hajiakhoundi; Mansoureh Soleimani; Gholamali Shahidi; Mahmood Faramarzi

doi:10.1016/j.ibneur.2023.03.004

Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease: A cross-sectional study

IBRO Neurosci Rep. 2023 Mar 8:14:285-292. doi: 10.1016/j.ibneur.2023.03.004. eCollection 2023 Jun.

Authors

Affiliations

¹ Anatomy Department, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
² Cellular & Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
³ Dentistry School, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Neurology Department, Rasool Akram Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran.
⁵ Neurology Department, Firoozgar Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran.
⁶ Research center of pediatric infectious diseases, institute of immunology and infectious diseases, Rasool ‎Akram Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran.

Abstract

Introduction: Finding a non-invasive and repeatable tool has been recommended to make an accurate diagnosis of Alzheimer's disease (AD) and Parkinson's disease (PD).

Methods: 70 volunteers participated in three groups: 24 with mild dementia of AD, 24 in the first and second stages of PD, and 22 healthy controls. After valuing the scores of cognitive tests, the salivary levels of phosphorylated tau (p-tau), total alpha-synuclein (α-syn), and beta-amyloid 1-42 (Aβ)‏‎ proteins have been evaluated. Finally, the cutoff points, receiver operating characteristic (ROC), sensitivity, and specificity have been calculated to find accurate and detectable biomarkers.

Results: Findings showed that the salivary level of Aβ was higher in both PD (p < 0.01) and AD (p < 0.001) patients than in controls. Moreover, the level of α-syn in both PD and AD patients was similarly lower than in controls (p < 0.05). However, the level of p-tau was only ‎higher in the AD group than in the control (p < 0.01). Salivary Aβ 1-42 level at a 60.3 pg/ml cutoff point revealed an excellent performance for diagnosing AD (AUC: 0.81).

Conclusion: Evaluation of p-tau, α-syn, and Aβ 1-42 levels in the saliva of AD and PD patients could help the early diagnosis. The p-tau level might be valuable for differentiation between AD and PD. Therefore, these hopeful investigations could be done to reduce the usage of invasive diagnostic methods, which alone is a success in alleviating the suffering of AD and PD patients. Moreover, introducing accurate salivary biomarkers according to the pathophysiology of AD and PD should be encouraged.

Keywords: AD, Alzheimer's disease; Alzheimer's disease; Aβ, ‏‎ Beta-amyloid 1–42; BDRS, Blessed Dementia Rating Scale; Beta-amyloid; CSF, Cerebrospinal fluid; CT scan, Computed tomography scan; ELISA, Enzyme-linked immunosorbent assay; MDS-UPDRS, MDS-Unified Parkinson’s Disease Rating Scale; MMSE, MCI (mild cognitive impairment mini-mental state examination; MRI, Magnetic resonance imaging; MoCA, Montreal Cognitive Assessment; NFTs, Neurofibrillary Tangles; NIA-AA, National Institute on Aging-Alzheimer’s Association; PD, Parkinson's disease; Parkinson's disease; Phosphorylated tau; ROC, Receiver operating characteristic; Total alpha-synuclein; p-tau, Phosphorylated tau; α-syn, Total alpha-synuclein.